Age-Adjusted Years of Potential Life Lost (YPLL) Rates Due to Ovarian Cancer in Chile During 2002-2019
Speaker(s)
dos Santos F1, Caputo M2, Romero JF2
1GSK, Santiago, RM, Chile, 2GSK, Santiago, Chile
Presentation Documents
OBJECTIVES: In Chile, Ovarian Cancer (OC) was included in the Explicit Health Guarantees (GES) program in 2013, guaranteeing diagnosis and treatment. However, little is known about the Years of Potential Life Lost (YPLL) due to OC, especially by age groups and in the Chilean regions, therefore, our objective was to analyze it considering 2002-2019 period.
METHODS: OC deaths (ICD-10 C56, C57.0, C48.1, C48.2, regardless of histological type) were extracted from Department of Health Statistics and Information, and population projection from National Statistics Institute. Age-adjusted YPLL rates/100,000 inhabitants were estimated for Chile and its 7 most populous regions by the direct method considering 80-year life expectancy, using the 2022 population as a reference. Postmenopausal women (50-64) and 3rd age (65-79) were analyzed. The total period was evaluated and stratified into 2002-2013 (pre-GES) and 2014-2019 (post-GES) and assessed qualitative.
RESULTS: Postmenopausal women presented the highest YPLL rates pre (average: 44.6) and post-GES (average: 43.2), a 3% change, followed by 3rd age women (average: 19.1) and post-GES (average: 19.2), a 0.4% change. Metropolitan Region presented mean change of 4% (postmenopausal: pre-GES: 42.4 vs post-GES 40.7) and 6% (3rd age: pre-GES: 19.2 vs post-GES 18.0), where AAMR slowly decreased during 2015-2019 (postmenopausal: 45, 44, 41, 42, 37 and 3rd age: 22, 18, 21, 16, 15). Rising YPLL in recent years were only identified at O’Higgins Region in postmenopausal (2014-2019: 6, 21, 39, 35, 40, 62) and at La Araucanía Region in the 3rd age group (2014-2019: 12, 11, 18, 20, 27, 30).
CONCLUSIONS: Mean YPLL rates post-GES had an overall decrease. However, in certain regions rising rates were observed in recent years. These results must be further studied to understand the causes and design appropriate public health actions.
Funding: GSK [222625].Code
EPH248
Topic
Epidemiology & Public Health
Topic Subcategory
Public Health
Disease
No Additional Disease & Conditions/Specialized Treatment Areas, Oncology